Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Why is the Alcidion share price crashing 27% to a 52-week low?
400% organic growth in 3 years: The ASX small-cap Cyan is pumped about
An unloved ASX stock I'm considering buying with $5,000 in August
Alcidion share price charges 9% ahead on record quarter
Small Cap Shares
'Upside surprise': 2 small-cap ASX shares ready to break out
Leading brokers name 3 ASX shares to buy today
ASX shares: Invest in these 2 stocks for a legit chance at $1 million
Share Market News
3 ASX All Ordinaries shares getting hammered on quarterly updates
Skin in the game: The ASX share in my portfolio I'm most excited about
Small Cap Shares
3 battered small-cap ASX shares we're still backing: expert
Share Market News
Top fund manager thinks ASX could start to move decisively higher, potentially sooner than you might be expecting
Top ASX shares to buy in September 2022
No, Alcidion does not pay dividends at this time.
Alcidion listed on the ASX on 24 June 2011.
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Alcidion Group Ltd (ASX: ALC) is a provider of intelligent informatics software for the healthcare sector.
The company builds, sells, delivers, runs, and supports solutions for healthcare providers. These include clinical, analytical, managerial, and administrative systems.
Its products include its Miya suite, a Fast Healthcare Interoperability Resources (FHIR) system that allows comprehensive healthcare data to be exchanged between different computer systems. Other products include Smartpage and Patientrack software.
Alcidion derives the majority of its revenue from its Australia/New Zealand segment and also has a presence in the United Kingdom.
|08 Dec 2023||$0.07||$0.00||0.00%||1,228,680||$0.07||$0.07||$0.07|
|07 Dec 2023||$0.07||$0.00||0.00%||533,263||$0.07||$0.07||$0.07|
|06 Dec 2023||$0.07||$0.00||0.00%||678,875||$0.07||$0.07||$0.07|
|05 Dec 2023||$0.07||$0.00||0.00%||1,341,794||$0.07||$0.07||$0.07|
|04 Dec 2023||$0.07||$0.00||0.00%||619,109||$0.07||$0.08||$0.07|
|01 Dec 2023||$0.07||$0.00||0.00%||227,198||$0.07||$0.08||$0.07|
|30 Nov 2023||$0.07||$0.00||0.00%||1,105,723||$0.08||$0.08||$0.07|
|29 Nov 2023||$0.07||$0.00||0.00%||553,319||$0.08||$0.08||$0.07|
|28 Nov 2023||$0.08||$0.00||0.00%||360,557||$0.08||$0.08||$0.08|
|27 Nov 2023||$0.08||$0.00||0.00%||2,214,353||$0.07||$0.08||$0.07|
|24 Nov 2023||$0.07||$0.00||0.00%||1,293,847||$0.07||$0.07||$0.07|
|23 Nov 2023||$0.07||$0.01||15.87%||5,789,715||$0.06||$0.07||$0.06|
|22 Nov 2023||$0.06||$-0.01||-14.49%||4,759,925||$0.07||$0.07||$0.06|
|21 Nov 2023||$0.07||$0.00||0.00%||5,466,898||$0.07||$0.07||$0.07|
|20 Nov 2023||$0.07||$0.00||0.00%||2,078,406||$0.07||$0.07||$0.07|
|17 Nov 2023||$0.07||$0.00||0.00%||4,106,596||$0.07||$0.07||$0.07|
|16 Nov 2023||$0.07||$0.00||0.00%||1,342,412||$0.07||$0.07||$0.07|
|15 Nov 2023||$0.07||$0.00||0.00%||2,462,681||$0.07||$0.07||$0.07|
|14 Nov 2023||$0.07||$0.00||0.00%||1,481,523||$0.07||$0.07||$0.07|
|13 Nov 2023||$0.07||$0.00||0.00%||911,436||$0.07||$0.07||$0.07|
|10 Nov 2023||$0.07||$0.00||0.00%||1,988,362||$0.07||$0.07||$0.07|
|05 Sep 2023||Victoria Weekes||Buy||100,000||$12,000||
|09 May 2023||Daniel Sharp||Buy||210,000||$20,230||
|05 May 2023||Daniel Sharp||Buy||590,000||$55,191||
|03 May 2023||Rebecca Wilson||Buy||250,000||$24,250||
|Ms Rebecca Wilson||Non-Executive DirectorNon-Executive Chairman||Jul 2017||
Ms Wilson is an experienced company director and Board advisor in Australia, UK and US and has more than 25 years of experience working within the healthcare, technology and life science sectors. She provides advice on complex stakeholder communication, issues management, investor and corporate relations, and business strategy to private and public companies, corporations, governments, and asset managers. She has mature governance and risk management experience.
|Mr Simon Chamberlain||Non-Executive Director||Jul 2019||
Mr Chamberlain is an accomplished executive and business leader, with more than 20 years experience in executive roles at companies including Experian (LON: EXPN), Medibank Private (ASX: MPL), Qantas (ASX:QAN) and MedAdvisor (ASX:MDR). He is currently the Chief Revenue Officer at the high-growth, techenabled residential services business, Detector Inspector, where he runs the sales, marketing, support and strategy functions. Simon has a proven track record for strategic success and commercial growth across a range of industries and markets. Simon led Qantas entrance into the online hotels business, establishing a profitable, high growth new division. At Medibank, Simon had responsibility across customer channels, data and customer experience. Gaining a better understanding of the complex challenges facing the wider health system led to Simons role leading strategy for MedAdvisor, where he supported the global expansion of its health technology business. Simon brings a valuable international perspective and global network to the Alcidion Board, holding executive roles across the US and the UK, where he was a key part of the executive team that sold the Australian start-up, Hitwise, to Experian in 2007. He is also a member of risk committee.
|Ms Victoria Weekes||Non-Executive Director||Sep 2021||
Ms Weekes is an non-executive director with experience across a diverse range of industries built on a successful executive career in investment markets and financial services. Victorias 30 years of experience in the finance and banking sector includes Csuite roles as a Managing Director at Citigroup and Executive General Manager at Westpac. As the immediate past Chair of the Sydney Local Health District, Victoria has a deep understanding of the healthcare sector where she served as Chair of its Education & Research Committee and Deputy Chair. Recognised for her specialist expertise in risk management and regulation having led organisations through strategic issue management and transformational change, Victoria is Deputy Chair of the ASIC Markets Disciplinary Panel, immediate past Chair of the NSW Treasury Audit & Risk Committee and President of the Financial Services Institute of Australasia (FINSIA). Until recently Victoria was the Deputy Chair of St George Community Housing, NSWs largest non-government community and affordable housing provider and a member of the Council of the State Library of NSW. She is the chairman of risk committee.
|Ms Katrina (Kate) Elizabeth Doyle (Quirke)||Chief Executive OfficerExecutive DirectorManaging Director||Jul 2018||
Ms Doyle has been CEO of Alcidion since 2018, prior to which she was CEO of MKM Health until it was acquired by Alcidion. She has been involved in large systems procurements and implementations of healthcare information technology across Australia, United Kingdom, New Zealand and Southeast Asia. Her background involves holding leading management roles at some of the largest healthcare software firms where she has had an impact on strategic product direction across
the health sector and believes astute application of information technology will support the transformation of healthcare delivery worldwide.
|Mr Daniel Sharp||Non-Executive Director||Sep 2021||
Originally commencing his career as a lawyer,Mr Sharp has over 25 years senior executive experience in investment banking and corporate finance. From 2012-2020, Daniel was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Daniel headed the corporate finance division at two of Australias leading independent Investment Banking/Stockbroking firms. Daniel has managed the IPOs, capital raisings and corporate advisory activities for many successful ASX listed companies in the healthcare, technologies and general industrials sectors. He is closely connected to strong networks of institutional, family office and high net worth investors both in Australia and overseas. he is also a member of risk committee.
|Ms Melanie Jaye Leydin||Company Secretary||Mar 2019||
|Melanie Jaye Leydin||Company Secretary||
|J P Morgan Nominees Australia Pty Limited||139,803,795||11.02%|
|Mr Malcolm Pradhan||134,582,403||10.61%|
|Mr Raymond Howard Blight||75,801,020||5.98%|
|Citicorp Nominees Pty Limited||58,449,895||4.61%|
|Rewmicman Pty Ltd <Smallman Family A/C>||29,810,441||2.35%|
|Mrs Katrina Elizabeth Doyle||27,793,199||2.19%|
|Caledonia Nominees Pty Ltd <Caledonia A/C>||19,976,377||1.58%|
|MNMD Pty Ltd <Quirke Super Fund A/C>||18,668,086||1.47%|
|Rangiora-London Pty Limited <Rangiora-London A/C>||9,800,000||0.77%|
|Sandhurst Trustees Ltd <Cyan C3G Fund A/C>||9,469,114||0.75%|
|Bnp Paribas Noms Pty Ltd <Drp>||9,129,104||0.72%|
|Hsbc Custody Nominees (Australia) Limited||8,651,688||0.68%|
|Mr Dean Anthony Mackenzie||8,270,080||0.65%|
|Mr Paul John Van Dyk||7,277,866||0.57%|
|Isle Of Wight Pty Limited <Mackinnon Family A/C>||6,980,867||0.55%|
|Emerald Shares Pty Limited <Emerald Unit A/C>||6,850,000||0.54%|
|Hudson Retirement Pty Ltd <Seagulls Super A/C>||6,524,244||0.51%|
|Mr Vivek Ramakrishnan + Miss Nisha Srinivasan||6,033,121||0.48%|
|Superhero Securities Limited <Client A/C>||5,602,157||0.44%|
|Beale & Co Pty Ltd||5,066,134||0.40%|